

4DMedical progresses to a commercial agreement with Qscan

24 January 2025

Highlights

- Following a successful pilot, 4DMedical progresses to a commercial agreement with Qscan
- Agreement marks 4DMedical's first Australian contract to incorporate products from both its Pulmonary Function and Pulmonary Structure suites, including CT LVAS™

Melbourne, Australia, 24 January 2025: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") today announces the signing of a commercial contract with Qscan Radiology Clinics ("Qscan"), a leading provider of diagnostic imaging services in Queensland. This agreement follows a successful pilot of 4DMedical's products with Qscan, and represents the first Australian contract to incorporate products from both the Pulmonary Function and Pulmonary Structure suites, including CT LVAS™.

Pilot success leads to commercial agreement

With 40 clinics across Queensland, New South Wales, ACT, Tasmania, and Western Australia, Qscan is one of Australia's leading medical imaging providers, offering a comprehensive range of diagnostic and interventional radiology services.

Following the success of a pilot program, which demonstrated the clinical and operational effectiveness of 4DMedical's proprietary suite of products, 4DMedical and Qscan have entered a commercial arrangement under which Qscan will offer 4DMedical's respiratory imaging solutions at select practices in Brisbane.

This agreement marks 4DMedical's first Australian commercial contract to incorporate products from both its Pulmonary Function and Pulmonary Structure suites. Specifically, the agreement with Qscan will provide clinicians with access to CT LVAS™, Lung Density Analysis™ - Inspiration (LDAi), Functional Lung Density Analysis™ (LDAf), and Lung Texture Analysis™ (LTA), each providing advanced diagnostic capabilities to support referrers and patients.

Reports will be delivered and billed on a Software-as-a-Service model on terms in line with those of the Company's other commercial partners.

4DMedical MD/CEO and Founder Andreas Fouras said:

Having completed our pilot with Qscan, we are excited to have progressed to a commercial agreement. This partnership ensures that more patients and clinicians have access to detailed, actionable insights into lung health, supporting better healthcare outcomes.

Momentum continues to build with the commercialisation of our technology across the US and Australia. With the addition of Qscan to our network of providers in Australia, I am excited to see our footprint expand to ensure our cutting-edge technology is now becoming more readily available to all Australians.

–ENDS–

Authorised by the 4DMedical Board of Directors.



Contacts

Corporate

Chief Financial Officer
Simon Glover
sglover@4dmedical.com

Administration

Company Secretary
Naomi Lawrie
companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical's innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of **Imbio**, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit www.4dmedical.com